IVD Can Contribute to t-mAb Effectiveness

Therapeutic monoclonal antibodies are useful therapies but in some cases they work for a period, then lose their effectiveness The role of testing in preventing therapeutic monoclonal antibodies from failing has recently received high-profile attention, with a session at AACC and in other places This blog piece by Kalorama analyst Rob Camp, PhD, looks at the role of testing.


AHCA, Obamacare Repeal, and the In Vitro Diagnostics (IVD) Industry

AHCA, Obamacare Repeal, and the In Vitro Diagnostics (IVD) Industry

Diagnostics companies seek to resolve four main policy issues, according to industry interviews and public statements


What is the Size of the Indonesian IVD Market?

What is the Size of the Indonesian IVD Market?

With a combination of hospitals and community health centers, public and private laboratories, the sprawling Southeast asian nation's rising middle class presages a growing IVD market. This article discusses the Indonesian IVD market, including growth factors and multiple segments.


Brazil Demands More, Fueling IVD Market

Brazil Demands More, Fueling IVD Market

Private healthcare spending can be the difference between a strong market or an under-performing one. In many emerging markets, the first thing to develop once consumers obtain more economic strength is disease detection. That bodes well for the Brazil IVD market.


Despite Slowdown Fears, No Change in China IVD Forecast

Despite Slowdown Fears, No Change in China IVD Forecast

Despite a growing concern about a slowdown in the Chinese economy, Kalorama Information does not see a lower estimate for the IVD industry. A few months ago we estimated that in 2014, the IVD market in China was $2.2 billion and is expected to show annual growth of 14.1% to reach $4.2 billion in 2019. We still see that estimate as most likely. The breakneck expansion of the past has tempered, underlying characteristics of the Chinese market - large population in need of healthcare will support c...


Sale of a Third Siemens Healthcare Unit: Will The Company Stay in IVD?

Sale of a Third Siemens Healthcare Unit:  Will The Company Stay in IVD?

If the recent sale of its audiology unit was the only such move made this year, there would be no question about the place of Siemens in the healthcare market. But this recent sale is one of three. Siemens is the third largest company in IVD, according to Kalorama Information’s biennial survey of the IVD market, with 5.5 billion in IVD revenues last year. In July Siemens agreed to sell its clinical microbiology business to Beckman Coulter, a subsidiary of Danaher Corp. Then In August, Cerner bou...